Register for free to
view the full innovation profile.
This technology is a series of small molecule inhibitors designed to treat Acute Lymphocytic Leukemia (ALL).
About
This technology is a series of small molecule inhibitors designed to treat Acute Lymphocytic Leukemia (ALL), a rapidly progressing cancer affecting lymphoid blood cells and bone marrow. The disease progresses rapidly and creates immature blood cells rather than mature ones. The leukemia cells are carried in the bloodstream to other organs and tissues where they continue to grow and divide, spreading to different organs. There is a need for effective treatment options for ALL as outcomes for patients (who went through chemotherapy) remain suboptimal. The 5-year overall survival is 30-40% in adults ALL patients and 85% in children.
This series of compounds has shown drug-like characteristics and minimal toxicity with reduced relapse rates, leading to better long-term health outcomes and decreasing the need for additional hospitalizations. These inhibitors demonstrate potent anticancer activity.
Key Benefits
- Potent: Demonstrated potent anticancer activity.
- Safer: Little to no toxicity, ensuring safer treatment options with fewer adverse effects for ALL patients.
- Drug-like: these molecules exhibit drug-like properties with IC50 in the same range as the clinically approved drug doxorubicin, supporting easier formulation and administration for patients.
- Better Outcomes: In vivo studies have demonstrated significant reductions in relapse rates, with some candidates showing little to no relapse or death up to 6 months.
Applications
- Acute Lymphocytic Leukemia (ALL) therapeutics